HCPS

InStep Health Welcomes Dave Marcou as Executive Director of Sales

Retrieved on: 
Tuesday, October 25, 2022
Health, Patient, Pharmacy, Marketing, Industry, OTC, Foot, CPG, HCPS, Knowledge, Public relations, Amusement arcade

CHICAGO, Oct. 25, 2022 /PRNewswire/ -- Instep Health announces the addition of Dave Marcou, Executive Director, Client Solutions, to its sales leadership team.

Key Points: 
  • CHICAGO, Oct. 25, 2022 /PRNewswire/ -- Instep Health announces the addition of Dave Marcou, Executive Director, Client Solutions, to its sales leadership team.
  • Dave brings more than 25 years of marketing and sales experience to InStep Health, where he'll spearhead an expansion of its consumer product goods corporate portfolio.
  • InStep Health adds Dave Marcou, Executive Director, Client Solutions, to spearhead the expansion of its CPG portfolio.
  • Dave shares, "There is great potential for clients who work with InStep Health to reach patients and providers through their healthcare journey.

Indegene acquires CultHealth, a full-service, healthcare marketing agency to elevate brand experience

Retrieved on: 
Wednesday, October 19, 2022
Physician, Health, Medicine, Culture, MOA, Efficiency, CRM, DTC, Patient, Medication, NEW, Mechanism of action, Drug discovery, Acquisition, Marketing, TV, CEO, Social media, Diabetes, Seyfarth Shaw, GLOBE, LLP, Solution, HCPS, Pharmaceutical industry, Management, Medical device, Indegene

CultHealth is a U.S.-based, full-service, healthcare marketing agency with significant experience in medical strategy, creative and omnichannel planning services.

Key Points: 
  • CultHealth is a U.S.-based, full-service, healthcare marketing agency with significant experience in medical strategy, creative and omnichannel planning services.
  • With CultHealth, our life sciences clients benefit from partnering with a single service provider, all the way from brand strategy through commercialization.
  • We believe that together we can build outstanding brand experiences, improve the effectiveness and efficiency of life sciences commercialization, and enable future ready healthcare.
  • To learn more, please visit www.indegene.com
    CultHealth is a full-service advertising and marketing agency focused on the unique needs of healthcare marketers.

Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals

Retrieved on: 
Tuesday, October 18, 2022
News, LinkedIn, FSE, Cannabis, Cannabidiol, Pharmacy, TSX, Health, Dermatology, Gaps, Education, HCPS, Patient, Hospital, Research, Twitter, Instagram, Pain management, Lists of diseases, Facebook, Risk, Knowledge, R, RHO, Company, Neurology, CEO, Absorption, Social media, GLOBE, HCP, Chronic pain, Formulary, Wellness, Platform, SEDAR, Medicine, Risk management, Medical device, Pharmaceutical industry

TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has launched its medical cannabis education portal, ”Avicenna Academy”, a no-cost resource and medical education portal for Health Care Professionals (“HCPs”). The medical education portal is designed to support HCPs through education and practical information with respect to the potential use of medical cannabis, with a view towards expanding access as well as measuring patient outcomes.

Key Points: 
  • The medical education portal is designed to support HCPs through education and practical information with respect to the potential use of medical cannabis, with a view towards expanding access as well as measuring patient outcomes.
  • Towards that goal, Avicannas medical team has combined its research and development expertise with cannabinoid formulations utilizing advanced drug delivery systems.
  • Access to the Avicenna Academy will be offered at no cost for HCPs to support necessary education and training.
  • If you are a Healthcare Professional and would like to learn more about using medical cannabis in your practice, please visit Avicenna Academy .

H1 Unveils New Brand on the Heels of Significant Financial, Customer and Product Capabilities Growth

Retrieved on: 
Tuesday, October 18, 2022
Universe, Adoption, Growth, Science, Forbes, HCPS, Patient, Health equity, Library and information science, Empowerment, Data management, Faculty, Medical Affairs Bureau, Acquisition, KOL, GLOBE, HCP, BISU Visual Identity, ARR, Solution, List of life sciences, Global health, Pharmaceutical industry, Tech

To date, H1 has realized a 177.8% growth in customers and 63% growth ARR YoY.

Key Points: 
  • To date, H1 has realized a 177.8% growth in customers and 63% growth ARR YoY.
  • We are pulling together disparate data sources and generating transformational, AI-powered insights to make H1 the cohesive, one-stop shop for all healthcare-related questions.
  • The new visual identity illuminates how H1 brings HCPs and the world in which they operate into focus through intelligent analytics solutions like those H1 brings to market.
  • H1 plans to continue introducing new capabilities and solutions to expand access around the world to the best doctors and therapies and increase global health equity.

Rare Expertise Announces the Launch of the Rare Medical Network

Retrieved on: 
Thursday, October 20, 2022
Physician, News, SAN, Global Genes, Disease, Equal, NPI, Diagnosis, Education, RMN, Patient, Publication, Multimedia, Partnership, INT, Degenerative disease, International Journal of Environmental Research and Public Health, Industry, Internet, Awareness, Social media, Database, PLD, HCPS, Pharmaceutical industry, Medical device, Travel

SAN DIEGO and MONTGOMERY, Texas, Oct. 20, 2022 /PRNewswire/ -- Rare Expertise, the company founded in 2015 with the mission of shortening the rare disease patient journey for diagnosis and treatment, is pleased to announce the launch of the Rare Medical Network (RMN), a group of 16 specialty-specific rare disease online publications and associated e-newsletters.

Key Points: 
  • SAN DIEGO and MONTGOMERY, Texas, Oct. 20, 2022 /PRNewswire/ -- Rare Expertise, the company founded in 2015 with the mission of shortening the rare disease patient journey for diagnosis and treatment, is pleased to announce the launch of the Rare Medical Network (RMN), a group of 16 specialty-specific rare disease online publications and associated e-newsletters.
  • To address the challenge, Rare Medical Network (RMN) online publications and e-newsletters are designed to educate healthcare providers on the diagnosis and management of rare diseases - within their own specialty.
  • The RMN and Equals 5 partnership combines the user-focused, specialty-specific rare disease content provided by the Rare Medical Network with the unique targeting and reporting capabilities of Equals 5 to better educate HCPs about rare diseases.
  • The Rare Medical Network can also reach over 500,000 healthcare professional specialists through its proprietary email database.

Mauro Usability Science Announces 3 New Advanced Human Factors Research and Usability Testing Methodologies for Medical Products

Retrieved on: 
Wednesday, October 19, 2022
Molecule, IFU, PFS, Cost reduction, Method, Risk, Particle-size distribution, Patient, Research, Functional, Emotion, Syringe, FDA, MUS, HCPS, Engineering, Medical device, Risk management, Newtonian

NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Founded in 1975, MUS is a leading provider of human factors research and usability testing services for medical products requiring FDA submission.

Key Points: 
  • NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Founded in 1975, MUS is a leading provider of human factors research and usability testing services for medical products requiring FDA submission.
  • This produces a roadmap for medical products that have emotional resonance and robust human factors benefits for designated medical professionals.
  • More
    Method 3 AGILE Medical Product FDA Summative Human Factors / Usability Testing for Risk and Cost Reduction.
  • Our experience reveals that a surprising number of medical products arrive at summative testing with serious usability problems.

APCER Life Sciences Awarded ISO 9001:2015 Certification: Validating its Unwavering Commitment to Excellence in Quality

Retrieved on: 
Tuesday, October 18, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Data Management, Technology, United Kingdom Accreditation Service, ISO, Risk management, Physician, Culture, Achievement, Quality management system, Certification, UKAS, Pharmacovigilance, Medical writing, QMS, Medication, ISO 9001, HCPS, Compliance, Medical device, Audit, Biotechnology

APCER Life Sciences, the preferred services provider for Pharmaceutical and Biotech companies looking for compliance solutions across the drug life cycle, has been awarded the ISO 9001:2015 Quality Management System certification.

Key Points: 
  • APCER Life Sciences, the preferred services provider for Pharmaceutical and Biotech companies looking for compliance solutions across the drug life cycle, has been awarded the ISO 9001:2015 Quality Management System certification.
  • Achieving this certification further endorses APCERs commitment to process adherence and effectiveness towards quality of services.
  • APCER Life Sciences, part of the APC Group, sees value in the achievement of this important milestone.
  • The certification establishes that APCER processes are measurable, continuously monitored and follow global standards, said Dr. Vineet Kacker, Managing Director and Global Technical Head, APCER Life Sciences.

PulsePoint launches Authenticated NPI™ With Medscape Data; Becomes First and Only Platform Offering Access to 100% Verified and Opted-In HCPs

Retrieved on: 
Tuesday, October 18, 2022
NPI, PulsePoint, Workflow, Patient, Privacy, Authentication, Internet Brands, Technology, ROI, Goal, Health, Behavior, KKR, Advertising, HCP, Life, Solution, HCPS, WebMD, Public relations, Risk management, Medscape

NEW YORK, Oct. 18, 2022 /PRNewswire/ -- PulsePoint, a technology company revolutionizing health decision-making in real-time, announced the launch of Authenticated NPI today.

Key Points: 
  • NEW YORK, Oct. 18, 2022 /PRNewswire/ -- PulsePoint, a technology company revolutionizing health decision-making in real-time, announced the launch of Authenticated NPI today.
  • This provides clients access to 3.2 million US NPIs who are first-party validated Medscape audiences and 100% opted in.
  • This workflow incorporates a first-party relationship with the HCP through Medscape along with a series of AI-driven technology to understand every HCP's digital touchpoint along their journey.
  • Unlike other platforms reaching NPIs based on email addresses sourced from third parties, campaigns served by PulsePoint's programmatic media platform, Life by PulsePoint , are now utilizing Authenticated NPItechnology and are guaranteed to reach verified HCPs.

Worldwide Portable Medical Devices Industry to 2027 - North America to Emerge as a Leader - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Medical Devices, Health, Adoption, CAGR, DX, Patient, APAC, Palliative care, Prevalence, Growth, HCPS, Medical device

Seeing the rising demand for portable medical devices, prominent players in the portable medical devices market are pursuing robust R&D endeavors.

Key Points: 
  • Seeing the rising demand for portable medical devices, prominent players in the portable medical devices market are pursuing robust R&D endeavors.
  • Advancements in emerging technologies are also boding well for the design and development of intelligent portable medical devices.
  • In the near future, the collective influence of these trends is expected to expand the global portable medical devices market.
  • On the other hand, the Asia Pacific is predicted to emerge as the fastest growing portable medical devices market amid rising consumer awareness and household income.

GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®

Retrieved on: 
Thursday, October 13, 2022
Health, Telemedicine, Virtual Medicine, Health Technology, Health Insurance, Pharmaceutical, Biotechnology, News, U.S. Securities and Exchange Commission, Time, Risk, Health care, SEC, Nausea, MS, Science, Degenerative disease, Multiple sclerosis, Workflow, Angioedema, Infection, Nobel Prize, HCPS, NASDAQ, Liver injury, Neuroscience, Patient, Biotechnology, Diarrhea, Abdominal pain, Spinal muscular atrophy, Selected Patient Information Resources in Asian Languages, Multimedia, Technology, Private Securities Litigation Reform Act, Progressive multifocal leukoencephalopathy, Solution, Anaphylaxis, Prescription, Disability, Shingles, Acquisition, Health, Dimethyl fumarate, Climate, BIIB, HCP, Clinical trial, Excipient, Brain, Intellectual property, Hypersensitivity, Death, Failure, US Organization, COVID-19, Lists of diseases, Pathology, Flushing, View, Pharmaceutical industry, Risk management, Biogen, GoodRx

HCPs who have decided to start patients with relapsing forms of multiple sclerosis (MS) on VUMERITY (diroximel fumarate) may now find the enrollment form and submit to the specialty hub through Provider Mode .

Key Points: 
  • HCPs who have decided to start patients with relapsing forms of multiple sclerosis (MS) on VUMERITY (diroximel fumarate) may now find the enrollment form and submit to the specialty hub through Provider Mode .
  • Announced today, GoodRxs Provider Mode is a new experience built specifically for HCPs to help them access solutions for the medications they prescribe.
  • We are proud to work with medical professionals to help patients with relapsing MS get the therapy they need more efficiently.
  • This exciting integration with Biogen is just the start of the great work to come as we expand our offerings for providers.